Robert Naviaux

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Source: gordonmedical.com

Robert K. Naviaux, MD, PhD, is a Professor in Residence at the University of California, San Diego, California, US. His work "has focused on the role of mitochondrial DNA replication, copy number regulation, DNA damage, and nucleotide signaling in development, aging, healing and regeneration in mitochondrial mechanisms of disease and development."[1] He was invited to join the Open Medicine Foundation's research team in 2016, following a announcement that the ME/CFS Severely Ill, Big Data Study had a significant result in the area of mitochondria.[2]

Dr. Naviaux directs the Robert Naviaux Laboratory at University of California, San Diego (UCSD) whose work is "divided into two groups: 1) Mitochondrial Mechanisms of Disease and Development, and 2) Evolutionary Systems Biology and Marine Metagenomics."[3] He is founder and co-director of the Mitochondrial and Metabolic Disease Center at UCSD, the co-founder and a former president of the Mitochondrial Medicine Society, as well as, a founding associate editor of the journal, Mitochondrion.[2]

Dr. Naviaux "discovered the cause and created the diagnostic test for Alpers syndrome, a mitochondrial disease... [and] is the director of the first FDA-approved clinical trial to study suramin [an antiparasitic drug] as a treatment for autism."[2][4]

Currently, Dr. Naviaux is using his mitochondria expertise, especially in metabolomics, to look for a biomarker and potential treatment for ME/CFS.[5]

In May 2016, a study was launched, led by Dr. Naviaux and Dr. Ronald Davis, in collaboration with Dr. Eric Gordon, Dr. Paul Cheney, and the Stanford Genome Technology Center in order "to validate earlier findings of a possible diagnostic signature for ME/CFS by measuring metabolites and to evaluate the contribution of genetics to the variation in observed metabolic signatures in this disease." The initial phase, with a total of 90 participants, has been completed and suggests "the mitochondria is in hypometabolism due to a chronic cell danger response state in ME/CFS patients."[6]

Education[edit | edit source]

  • 1977-1978 - Undergraduate (Biochemistry), Georg August Universität, Göttingen, Germany
  • 1979 - B.S. (Biological Sciences), University of California, Davis, California
  • 1981 - M.S. (Zoology), Indiana University, Bloomington, Indiana
  • 1986, 1989 - M.D., Ph.D. (Genetics, Virology), Indiana University School of Medicine, Indianapolis, Indiana
  • 1986-1990 - Internship and Residency, Internal Medicine, American Board of Internal Medicine (ABIM), Clinical Investigator Pathway, University of California, Davis
  • 1990-1994 - Postdoctorate (Retrovirology, Gene Therapy), The Salk Institute, La Jolla, California
  • 1994-1997 - Fellowship (Biochemical Genetics, mtDNA Replication), University of California, San Diego Medical Center, San Diego, California

Notable studies[edit | edit source]

  • Nov 15, 2016, Reply to Vogt et al.: Metabolomics and chronic fatigue syndrome[9]
  • Feb 7, 2017, Reply to Roerink et al.: Metabolomics of chronic fatigue syndrome[10]
  • 2017, A robust, single-injection method for targeted, broad-spectrum plasma metabolomics[11](Full Text)
  • 2020, Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome[12] (Full text)

Awards and Honors[edit | edit source]

  • 2002, Honored in a non-fiction book entitled, Anna’s Friends — Lessons Learned from a Short and Beautiful Life
  • 2007, Thomson ESI - Science Citation Index “Fast Moving Front Article”
  • 2007, United Mitochondrial Disease Foundation Mitochondrial Medicine - Best Abstract Award
  • 2008, Hailey’s Wish Foundation - Hailey’s Hero Award, For Outstanding Research and Clinical Care of children with mitochondrial disease

Talks and interviews[edit | edit source]

(with Spanish subtitles)[15]

Articles[edit | edit source]

Online presence[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ "Robert Naviaux | UCSD Profiles". profiles.ucsd.edu. Retrieved August 15, 2018.
  2. ↑ 2.0 2.1 2.2 "Welcome Dr. Naviaux to our Team | Open Medicine Foundation". Open Medicine Foundation. February 10, 2016. Retrieved August 15, 2018.
  3. ↑ "Naviaux Laboratory Genetics Research at UC San Diego". UC San Diego School of Medicine. Retrieved August 15, 2018.
  4. ↑ LaFee, Scott (June 10, 2015). "Clinical Trial Launched to Assess Safety and Efficacy of Autism Drug Treatment". UC Health - UC San Diego. Retrieved August 15, 2018.
  5. ↑ "The Mitochondria Man Gets His Money and The UK Goes MEGA: ME/CFS Research Moving Forward". Health Rising's Chronic Fatigue Syndrome (ME/CFS) and Fibromyalgia Forums (Forum Discussion). May 19, 2016. Retrieved August 15, 2018.
  6. ↑ "Metabolomics and Genetics Study | Open Medicine Foundation". Open Medicine Foundation. Retrieved August 15, 2018.
  7. ↑ Naviaux, Robert K. (May 2014), "Metabolic features of the cell danger response", Mitochondrion, 16: 7–17, doi:10.1016/j.mito.2013.08.006, PMID 23981537
  8. ↑ Naviaux, Robert K; Naviaux, Jane C.; Li, Kefeng; Bright, A. Taylor; Alaynick, William A.; Wang, Lin; Baxter, Asha; Nathan, Neil; Anderson, Wayne; Gordon, Eric (September 13, 2016), "Metabolic features of chronic fatigue syndrome", PNAS, 113 (37), doi:10.1073/pnas.1607571113
  9. ↑ Naviaux, Robert K; Naviaux, Jane C.; Li, Kefeng; Bright, A. Taylor; Alaynick, William A.; Wang, Lin; Baxter, Asha; Nathan, Neil; Anderson, Wayne; Gordon, Eric (November 15, 2016), "Reply to Vogt et al.: Metabolomics and chronic fatigue syndrome", Proc Natl Acad Sci USA, 113 (46): E7142–E7143, doi:10.1073/pnas.1616261113
  10. ↑ Naviaux, Robert K; Gordon, Eric (February 7, 2017), "Reply to Roerink et al.: Metabolomics of chronic fatigue syndrome.", Proc Natl Acad Sci USA, 114 (6): E911-E912, doi:10.1073/pnas.1618984114
  11. ↑ Li, Kefeng; Naviaux, Jane C.; Bright, A. Taylor; Wang, Lin; Naviaux, Robert K (2017), "A robust, single-injection method for targeted, broad-spectrum plasma metabolomics", Metabolomics, 13 (122), doi:10.1007/s11306-017-1264-1
  12. ↑ Schreiner, Philipp; Harrer, Thomas; Scheibenbogen, Carmen; Lamer, Stephanie; Schlosser, Andreas; Naviaux, Robert K.; Prusty, Bhupesh K. (April 1, 2020). "Human Herpesvirus-6 Reactivation, Mitochondrial Fragmentation, and the Coordination of Antiviral and Metabolic Phenotypes in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome". ImmunoHorizons. 4 (4): 201–215. doi:10.4049/immunohorizons.2000006. ISSN 2573-7732. PMID 32327453.
  13. ↑ Naviaux, Robert K. (January 27, 2013). "Mitochondria and Autism (Spring 2011) - Robert K. Naviaux, M.D., Ph.D." YouTube. Saul Colquhoun.
  14. ↑ Naviaux, Robert (September 28, 2017). "Robert Naviaux, MD, PhD | ME/CFS Cell Danger Response, Metabolic Features, Low-energy in Nature". YouTube. Open Medicine Foundation - OMF.
  15. ↑ Naviaux, Robert (August 13, 2017). "PART 2 ME CFS Symposium at Stanford trimmed". YouTube. Asociación Síndrome Fatiga Crónica-SQM.
  16. ↑ Johnson, Cort (May 19, 2016). "The Mitochondria Man Gets His Money and The UK Goes MEGA: ME/CFS Research Moving Forward - Health Rising". Health Rising. Retrieved August 15, 2018.
  17. ↑ "UCSD Researcher Suggests Chronic Illness Could Be Breakdown in Normal Healing - Times of San Diego". Times of San Diego. September 7, 2018. Retrieved September 13, 2018.
  18. ↑ "Naviaux Lab". naviauxlab.ucsd.edu. Retrieved August 15, 2018.
  19. ↑ Rodakis, John (January 15, 2015). "N of One | Promising Research Update". N of One: Autism Research Foundation. Retrieved August 15, 2018.
Retrieved from "https://me-pedia.org/w/index.php?title=Robert_Naviaux&oldid=241537"